Form 8-K · Current Report · Filed 2026-09-01
ResMed Inc. Announces $450M Accelerated Share Repurchase Agreement
On August 31, 2026, ResMed Inc. entered into an accelerated share repurchase agreement with Citibank, N.A. to repurchase $450.0 million of its shares of common stock. The transaction is funded by the proceeds from the sale of its MatrixCare business and cash on hand. The repurchase is part of a previously announced repurchase authorization and is expected to be completed in December 2026.
- Filer
- ResMed Inc. RMD · NYSE
- Filed
- Accession
- 0001193125-26-378487
- CIK
- 0000943819
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$240.10
Since filing
+0.0%
Latest close
$240.10
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from RMD reporting the same item, with the next session's move:
Insider tape
Within 45 days of this filing, RMD insiders reported 4 Form 4 transactions — net selling of $2.1M.
About ResMed Inc.
ResMed Inc. is an innovative leader in the development and manufacturing of devices focused on improving the quality of sleep and respiratory health. Operating globally, ResMed specializes in producing advanced equipment for sleep apnea therapy, chronic obstructive pulmonary disease (COPD), and various respiratory conditions. The company's offerings include a range of cutting-edge products like continuous positive airway pressure (CPAP) devices, bilevel systems, and ventilators, designed to enhance patient comfort and compliance. ResMed is also at the forefront of integrating cloud-connected devices to support improved patient monitoring and telemedicine services. The healthcare industry, particularly the medical device sector, benefits significantly from ResMed's contributions, as the company aims to address the growing needs associated with sleep and respiratory conditions. By focusing on both personal and overarching health care solutions, ResMed plays a crucial role in enhancing patient quality of life, thereby solidifying its position as a key player in the global health and respiratory care markets.
Never miss another RMD filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.